$CGC

Lazzarato David Angelo sold $21K of CGC

Lazzarato David Angelo sold 22,380 shares of Canopy Growth Corp (CGC) at $0.93 on 2026-09-28.

Original reporting
SEC EDGAR · Lazzarato David Angelo
Published Sep 30, 2026, 8:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CGC
Neutral
medium confidence
Mentioned
$CGC
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CGCNeutralLow
01

Why it matters

The disclosed sale is small and unlikely to move the stock significantly, but it provides a data point for monitoring insider sentiment.

02

Market read

A routine insider sale with limited market impact; useful for tracking insider behavior but not a catalyst for immediate trading.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed in the filing.

Relevance 3/10Novelty 3/10Timing: post‑filing today

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$CGCNeutralMedium confidence
Context

Director Lazzarato sold 22,380 shares for $20,741, reducing his stake to 189,479 shares.

Expected impact

likely slight downward pressure as investors digest the director's sale

Evidence & confidence

The transaction size is small relative to market cap and typical daily volume, so impact is limited.

Market effects

Minimal; cannabis sector not materially affected by a single director's modest sale.

None

None

Counterpoint

The sale could be routine portfolio rebalancing and not indicative of company fundamentals.

Key entities

  • Canopy Growth Corp

    Cannabis producer listed on NYSE under ticker CGC.

  • Lazzarato David Angelo

    Director of Canopy Growth Corp.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CGCMed

Canopy Growth enters UK medical cannabis market

Canopy Growth (TSE: WEED, NASDAQ: CGC) will supply four medical cannabis strains to the UK market via GROW Group. This expands its international reach, with Europe contributing 12% of its Q2 revenue. Shares trade near 52-week lows. The company reported a narrowed adjusted loss and increased international revenue, driven by Poland. Competitors Aurora and Tilray have entered the UK market through acquisitions.

$CURLFHighAI 9/10

Curaleaf's Hostile Takeover Bid for Aurora Is Just the Tip of the Iceberg for Cannabis Consolidation. These 2 Stocks Could Be the Biggest Winners.

Curaleaf has made an unsolicited bid for Aurora Cannabis, offering a 45% premium. Aurora has not accepted the deal. Tilray Brands and Canopy Growth are also engaging in consolidation. Aurora recently acquired Safari Flower, while Canopy bought MTL Cannabis. Tilray is diversifying into alcohol and CBD. Investors should consider risks of consolidation strategies.

$CURLFHighAI 8/10

Curaleaf's Hostile Takeover Bid for Aurora Is Just the Tip of the Iceberg for Cannabis Consolidation. These 2 Stocks Could Be the Biggest Winners.

Curaleaf (CURLF) has made an unsolicited bid for Aurora Cannabis (ACB), offering a 45% premium. Aurora's response was noncommittal. Canopy Growth (CGC) and Tilray Brands (TLRY) are also consolidating, with Tilray expanding into alcohol and CBD. Investors may benefit from acquisitions, but risks include integration challenges and leverage.

$CGCMedAI 8/10

Cannabis Operator CGC Rises 15% in a Month: Time to Buy, Hold or Sell?

Canopy Growth Corporation (CGC) shares rose 15% in a month after reporting Q1 fiscal 2027 earnings that beat estimates, showing revenue growth and improved margins. The company's cannabis business is improving, with increased revenues and narrowing losses. However, cash flow remains a concern, and competition in the cannabis market is stiff. Analysts have slightly improved loss estimates but maintain a 'Hold' rating.